{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:00:11Z","timestamp":1786993211253,"version":"build-2736575974"},"reference-count":115,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpet.2025.103737","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:13:06Z","timestamp":1767082386000},"page":"103737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Using nanobodies for breast cancer treatment"],"prefix":"10.1016","volume":"392","author":[{"given":"Sapthala P.L.","family":"Galappaththi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Swingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.jpet.2025.103737_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313165","article-title":"The genomic and biologic landscapes of breast cancer and racial differences","volume":"25","author":"Galappaththi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103737_bib2","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12609-018-0295-6","article-title":"Bone-modifying agents in early-stage and advanced breast cancer","volume":"10","author":"Heeke","year":"2018","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.jpet.2025.103737_bib5","series-title":"Cancer: Disease Control Priorities, Third Edition (Volume 3)","article-title":"Radiation therapy for cancer","author":"Jaffray","year":"2015"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.jpet.2025.103737_bib7","series-title":"Cancer Chemotherapy","author":"Amjad","year":"2025"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000529260","article-title":"Off-target effects of cancer therapy on development of therapy-induced arrhythmia: a review","volume":"148","author":"Leiva","year":"2023","journal-title":"Cardiology"},{"issue":"6","key":"10.1016\/j.jpet.2025.103737_bib9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","article-title":"Chemotherapy use, performance status, and quality of life at the end of life","volume":"1","author":"Prigerson","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jpet.2025.103737_bib10","series-title":"Adverse Effects of Radiation Therapy","author":"Majeed","year":"2025"},{"issue":"3","key":"10.1016\/j.jpet.2025.103737_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PPO.0000000000000607","article-title":"Current state of cell therapies for breast cancer","volume":"28","author":"Gautam","year":"2022","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cbf.3676","article-title":"Gene therapy: a promising approach for breast cancer treatment","volume":"40","author":"Dastjerd","year":"2022","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.jpet.2025.103737_bib14","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","article-title":"Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients","volume":"16","author":"Zhang","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.jpet.2025.103737_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1375433","article-title":"New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy","volume":"15","author":"Chowaniec","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103737_bib17","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: a review of generation, diagnostics and therapeutics","volume":"24","author":"Jin","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/08923973.2015.1102934","article-title":"Single-domain antibodies for biomedical applications","volume":"38","author":"Krah","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.jpet.2025.103737_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1475-2859-10-44","article-title":"Biotechnological applications of recombinant single-domain antibody fragments","volume":"10","author":"de Marco","year":"2011","journal-title":"Microb Cell Fact"},{"issue":"31","key":"10.1016\/j.jpet.2025.103737_bib20","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1523\/JNEUROSCI.2728-06.2006","article-title":"Antibodies as valuable neuroscience research tools versus reagents of mass distraction","volume":"26","author":"Rhodes","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.jpet.2025.103737_bib21","author":"Hua"},{"issue":"8","key":"10.1016\/j.jpet.2025.103737_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I trial of 131I-GMIB-anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide Therapy in breast cancer patients","volume":"62","author":"D\u2019Huyvetter","year":"2021","journal-title":"J Nucl Med"},{"issue":"supplement 2","key":"10.1016\/j.jpet.2025.103737_bib23","article-title":"Dose escalation study to evaluate safety, dosimetry, and PD of the HER2-directed radioligand CAM-H2 in patients with advanced HER2+ breast, gastric, GEJ, and other HER2+ solid tumors (trial ID: NCT04467515)","volume":"65","author":"Gayton","year":"2024","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib24","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-24-3888","article-title":"Safety and efficacy of KN046 in combination with KN026 in patients with advanced HER2-positive breast cancer: a phase II trial","volume":"31","author":"Liu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"issue":"6151","key":"10.1016\/j.jpet.2025.103737_bib26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1126\/science.1241145","article-title":"Antibody therapeutics in cancer","volume":"341","author":"Sliwkowski","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jpet.2025.103737_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jcp.55.2.81","article-title":"Clinically useful monoclonal antibodies in treatment","volume":"55","author":"Drewe","year":"2002","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-020-0153-3","article-title":"Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond","volume":"6","author":"Costa","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jpet.2025.103737_bib29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1146\/annurev-immunol-042617-053327","article-title":"Exploiting nanobodies\u2019 singular traits","volume":"36","author":"Ingram","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103737_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fimmu.2017.00771","article-title":"Nanobody technology: a versatile toolkit for microscopic imaging, protein\u2013protein interaction analysis, and protein function exploration","volume":"8","author":"Beghein","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib31","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tibtech.2016.05.017","article-title":"Animal-friendly affinity reagents: replacing the needless in the Haystack","volume":"34","author":"Gray","year":"2016","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jpet.2025.103737_bib32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2021.05.004","article-title":"Nanobodies as efficient drug-carriers: progress and trends in chemotherapy","volume":"334","author":"Panikar","year":"2021","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103737_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","article-title":"Single domain antibodies: promising experimental and therapeutic tools in infection and immunity","volume":"198","author":"Wesolowski","year":"2009","journal-title":"Med Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0022-2836(94)90046-9","article-title":"Three-dimensional structures of the free and the antigen-complexed Fab from monoclonal anti-lysozyme antibody D44.1","volume":"243","author":"Braden","year":"1994","journal-title":"J Mol Biol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103737_bib36","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/prot.22974","article-title":"Modeling GPCR active state conformations: the \u03b2(2)-adrenergic receptor","volume":"79","author":"Simpson","year":"2011","journal-title":"Proteins"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79036-0","article-title":"High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme","volume":"10","author":"Esparza","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jpet.2025.103737_bib39","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/1751-7915.12819","article-title":"Escherichia coli surface display for the selection of nanobodies","volume":"10","author":"Salema","year":"2017","journal-title":"Microb Biotechnol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103737_bib40","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1074\/jbc.R115.679811","article-title":"Nanobodies as probes for protein dynamics in vitro and in cells","volume":"291","author":"Dmitriev","year":"2016","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.jpet.2025.103737_bib41","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsb0996-803","article-title":"Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme","volume":"3","author":"Desmyter","year":"1996","journal-title":"Nat Struct Biol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib42","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1073\/pnas.0505379103","article-title":"Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies","volume":"103","author":"De Genst","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jpet.2025.103737_bib43","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/emboj\/19.5.921","article-title":"Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire","volume":"19","author":"Nguyen","year":"2000","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.jpet.2025.103737_bib44","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/anie.201708459","article-title":"Nanobodies: chemical functionalization strategies and intracellular applications","volume":"57","author":"Schumacher","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.jpet.2025.103737_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.talanta.2015.10.027","article-title":"Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein","volume":"147","author":"Chen","year":"2016","journal-title":"Talanta"},{"issue":"2","key":"10.1016\/j.jpet.2025.103737_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003456","article-title":"Description of a nanobody-based competitive immunoassay to detect tsetse fly exposure","volume":"9","author":"Caljon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.jpet.2025.103737_bib48","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7150\/thno.52614","article-title":"The current landscape of antibody-based therapies in solid malignancies","volume":"11","author":"Shah","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.jpet.2025.103737_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cmmi.1637","article-title":"Molecular imaging of tumors with nanobodies and antibodies: timing and dosage are crucial factors for improved in vivo detection","volume":"10","author":"Bannas","year":"2015","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5732\/cjc.010.10542","article-title":"Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations","volume":"30","author":"Wykosky","year":"2011","journal-title":"Chin J Cancer"},{"issue":"2","key":"10.1016\/j.jpet.2025.103737_bib51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/diagnostics13020263","article-title":"Immunohistochemical HER2 recognition and analysis of breast cancer based on deep learning","volume":"13","author":"Che","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103737_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/era.10.226","article-title":"HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies","volume":"11","author":"Gajria","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"10.1016\/j.jpet.2025.103737_bib53","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1096\/fj.10-180331","article-title":"Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer","volume":"25","author":"Vaneycken","year":"2011","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib54","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/s41598-022-07006-9","article-title":"Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers","volume":"12","author":"Feng","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2025.103737_bib55","article-title":"A Novel small molecular antibody, HER2-nanobody, inhibits tumor proliferation in HER2-positive breast cancer cells in vitro and in vivo","volume":"11","author":"Yan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jpet.2025.103737_bib56","article-title":"A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib57","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/cancers11121826","article-title":"Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials","volume":"11","author":"Maennling","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jpet.2025.103737_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188789","article-title":"Can EGFR be a therapeutic target in breast cancer?","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"10.1016\/j.jpet.2025.103737_bib59","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/1061186X.2024.2449495","article-title":"Epidermal growth factor receptors unveiled: a comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors","volume":"33","author":"Manojmouli","year":"2025","journal-title":"J Drug Target"},{"issue":"3","key":"10.1016\/j.jpet.2025.103737_bib60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","article-title":"Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies","volume":"56","author":"Roovers","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.jpet.2025.103737_bib61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2010.03.020","article-title":"Downregulation of EGFR by a novel multivalent nanobody-liposome platform","volume":"145","author":"Oliveira","year":"2010","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12860-022-00412-x","article-title":"Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody","volume":"23","author":"Zeronian","year":"2022","journal-title":"BMC Mol Cell Biol"},{"key":"10.1016\/j.jpet.2025.103737_bib63","doi-asserted-by":"crossref","unstructured":"Heitrich M, Fernandez MM, Aguilar-Cortes DC, et al. Development of novel high-affinity nanobodies against EGFR for cancer therapy. Preprint. Posted Online March 16, 2025. bioRxiv. 2025.03.16.643542. https:\/\/doi.org\/10.1101\/2025.03.16.643542.","DOI":"10.1101\/2025.03.16.643542"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib64","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1007\/s11033-013-2790-1","article-title":"Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody","volume":"40","author":"Omidfar","year":"2013","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10.1016\/j.jpet.2025.103737_bib65","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1080\/07391102.2016.1192065","article-title":"Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches","volume":"35","author":"Farasat","year":"2017","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jpet.2025.103737_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2021.105888","article-title":"A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties","volume":"184","author":"Xi","year":"2021","journal-title":"Protein Expr Purif"},{"issue":"11","key":"10.1016\/j.jpet.2025.103737_bib67","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1517\/14712598.2013.833602","article-title":"Therapeutic antibodies to intracellular targets in cancer therapy","volume":"13","author":"Veomett","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jpet.2025.103737_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.573278","article-title":"Nanobody-based probes for subcellular protein identification and visualization","volume":"14","author":"de Beer","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12964-020-0527-z","article-title":"Role of STAT3 signaling pathway in breast cancer","volume":"18","author":"Ma","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"9","key":"10.1016\/j.jpet.2025.103737_bib70","first-page":"439","article-title":"STAT3 activation promotes angiogenesis in human breast cancer cells","volume":"68","author":"Kunigal","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jpet.2025.103737_bib71","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/0008-5472.CAN-15-2770","article-title":"STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis","volume":"76","author":"Jones","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib73","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1535-7163.MCT-20-0505","article-title":"Lipidome-based targeting of STAT3-driven breast cancer cells using poly-L-glutamic acid-coated layer-by-layer nNanoparticles","volume":"20","author":"To\u0161i\u0107","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jpet.2025.103737_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/1178223417750858","article-title":"Suppression of breast cancer cell proliferation by selective single-domain antibody for intracellular STAT3","volume":"12","author":"Singh","year":"2018","journal-title":"Breast Cancer (Auckl)"},{"issue":"7","key":"10.1016\/j.jpet.2025.103737_bib75","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/ijc.23215","article-title":"Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG","volume":"122","author":"Renz","year":"2008","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.jpet.2025.103737_bib76","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.7150\/thno.22523","article-title":"CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription","volume":"8","author":"Huang","year":"2018","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152683","article-title":"Prognostic and clinicopathological significance of CapG in various cancers: evidence from a meta-analysis","volume":"215","author":"Lang","year":"2019","journal-title":"Pathol Res Pract"},{"issue":"6","key":"10.1016\/j.jpet.2025.103737_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3585","article-title":"A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis","volume":"15","author":"Van Impe","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jpet.2025.103737_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111055","article-title":"An AKT2-specific nanobody that targets the hydrophobic motif induces cell cycle arrest, autophagy and loss of focal adhesions in MDA-MB-231 cells","volume":"133","author":"Merckaert","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib80","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1096\/fj.13-242537","article-title":"Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization","volume":"28","author":"Van Audenhove","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.jpet.2025.103737_bib81","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann Oncol"},{"issue":"19\u201320","key":"10.1016\/j.jpet.2025.103737_bib82","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.jpet.2025.103737_bib83","article-title":"Tumor microenvironment of cancer stem cells: perspectives on cancer stem cell targeting","volume":"11","author":"Guo","year":"2024","journal-title":"Genes Dis"},{"key":"10.1016\/j.jpet.2025.103737_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.754196","article-title":"Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103737_bib85","first-page":"81","article-title":"Tumor-infiltrating regulatory T cells: origins and features","volume":"7","author":"Deng","year":"2018","journal-title":"Am J Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103737_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"24","key":"10.1016\/j.jpet.2025.103737_bib88","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.jpet.2025.103737_bib89","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.slasd.2023.08.008","article-title":"Nanobodies: a game-changer in cell-mediated immunotherapy for cancer","volume":"28","author":"Mustafa","year":"2023","journal-title":"SLAS Discov"},{"issue":"8","key":"10.1016\/j.jpet.2025.103737_bib90","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib91","doi-asserted-by":"crossref","first-page":"768","DOI":"10.20517\/cdr.2023.58","article-title":"Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies","volume":"6","author":"Wong","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2017.4","article-title":"Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade","volume":"3","author":"Zhang","year":"2017","journal-title":"Cell Discov"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib93","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","article-title":"Nanobodies and their derivatives: pioneering the future of cancer immunotherapy","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jpet.2025.103737_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114002","article-title":"A super-long-acting anti-PD-L1 nanobody fused to elastin-like polypeptide for triple-negative breast cancer immunotherapy","volume":"385","author":"Yao","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.jpet.2025.103737_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib96","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: can we be more clever than cancer cells?","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"13","key":"10.1016\/j.jpet.2025.103737_bib97","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.3390\/cancers13133253","article-title":"New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis","volume":"13","author":"Larionova","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpet.2025.103737_bib98","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice","volume":"9","author":"Jayasingam","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jpet.2025.103737_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103737_bib100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ctrv.2018.08.010","article-title":"Tumor-associated macrophages in breast cancer: innocent bystander or important player?","volume":"70","author":"Qiu","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"10.1016\/j.jpet.2025.103737_bib101","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/0008-5472.CAN-11-2994","article-title":"Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages","volume":"72","author":"Movahedi","year":"2012","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jpet.2025.103737_bib102","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41423-019-0224-2","article-title":"Targeting natural killer cells in solid tumors","volume":"16","author":"Habif","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jpet.2025.103737_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106932","article-title":"NK cell receptors in anti-tumor and healthy tissue protection: mechanisms and therapeutic advances","volume":"270","author":"Greppi","year":"2024","journal-title":"Immunol Letters"},{"issue":"11","key":"10.1016\/j.jpet.2025.103737_bib104","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.3390\/ijms24119521","article-title":"NK Cells in cancer: mechanisms of dysfunction and therapeutic potential","volume":"24","author":"Portale","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jpet.2025.103737_bib105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/imcb.12658","article-title":"Advances in natural killer cell therapies for breast cancer","volume":"101","author":"Kiaei","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jpet.2025.103737_bib106","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.jpet.2025.103737_bib107","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.18632\/oncotarget.2093","article-title":"A Fc\u03b3RIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy","volume":"5","author":"Turini","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpet.2025.103737_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211010117","article-title":"Nanobody conjugates for targeted cancer therapy and imaging","volume":"20","author":"Kang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jpet.2025.103737_bib109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12935-024-03259-8","article-title":"Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies","volume":"24","author":"Abdolvahab","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jpet.2025.103737_bib110","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2147\/IJN.S399322","article-title":"131I-labeled anti-HER2 nanobody for targeted radionuclide therapy of HER2-positive breast cancer","volume":"18","author":"Zhao","year":"2023","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"10.1016\/j.jpet.2025.103737_bib111","doi-asserted-by":"crossref","first-page":"708","DOI":"10.7150\/thno.8156","article-title":"Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody","volume":"4","author":"D\u2019Huyvetter","year":"2014","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.jpet.2025.103737_bib112","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103737_bib113","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1021\/acs.molpharmaceut.8b01318","article-title":"Selective cytotoxicity to HER2 positive breast cancer cells by saporin-loaded nanobody-targeted polymeric nanoparticles in combination with photochemical internalization","volume":"16","author":"Mart\u00ednez-Jothar","year":"2019","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.jpet.2025.103737_bib114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.jpet.2025.103737_bib115","article-title":"Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy","volume":"5","author":"Li","year":"2024","journal-title":"MedComm (2020)"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652540250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652540250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:45:03Z","timestamp":1772127903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652540250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":115,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S002235652540250X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103737","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using nanobodies for breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103737"}}